Keywords: repligen, uridine, prodrug, bipolar, disorder, initiated, phase

Repligen to test uridine prodrug in bipolar disorder

Article | 27 January 2003

Print This

Repligen has initiated a Phase I/II clinical trial of RG2133, a prodrugof uridine, in patients with either bipolar disorder ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in